Connect with us

News

A common treatment for your knee osteoarthritis may be making it worse, studies say | CNN

Published

on

A common treatment for your knee osteoarthritis may be making it worse, studies say | CNN



CNN
 — 

A typical remedy for some arthritis ache would possibly truly be making the situation worse, based on two new research.

“Knee osteoarthritis is among the most persistent, degenerative and progressive situations, with an estimated incidence of 800,000 sufferers annually within the US alone,” mentioned lead writer of one of many research, Dr. Upasana Bharadwaj.

Osteoarthritis is a typical type of arthritis the place the cartilage inside a joint breaks down over time and the bones round it change, getting worse over time, based on the US Facilities for Illness Management and Prevention.

Advertisement

At the least 10% of the sufferers within the examine used injections to handle the ache, added Bharadwaj, who’s a postdoctoral analysis fellow within the division of radiology on the College of California San Francisco’s Faculty of Medication. Two of these ache administration injectables are corticosteroids, the extra widespread of the 2, and hyaluronic acid.

The research, which have been offered on the annual assembly of the Radiological Society of North America, used both radiograph or MRI photos to trace the development of osteoarthritis within the knees of sufferers. A few of these sufferers didn’t obtain any remedy and others bought corticosteroid or hyaluronic acid injections, based on the research.

Each papers confirmed a statistically vital improve in development of degenerative modifications in knee cartilage over two years in those who had corticosteroid injections in contrast with those that had hyaluronic acid or no injections, based on the examine authors.

Nonetheless, simply because the pictures would possibly look worse doesn’t all the time imply that the individuals are feeling extra ache, mentioned Azad Darbandi, lead writer of the opposite examine.

“You would possibly see that the knee seems unhealthy on a radiograph, however the affected person won’t be having worse signs,” added Darbandi, a researcher and medical scholar on the Chicago Medical Faculty of Rosalind Franklin College of Medication and Science.

Advertisement

The research spotlight a debate within the osteoarthritis scientific neighborhood concerning the function of modifications within the construction of the joint. Presently, ache is the primarily acknowledged symptom, mentioned Jason Kim, the Arthritis Basis’s vp of osteoarthritis analysis. Kim was not concerned in both examine.

The takeaway from the research is that corticosteroids must be administered with warning for osteoarthritis ache.

Hyaluronic acid injections could also be a promising choice for managing ache however is much less utilized as a result of there may be much less analysis, and most sufferers should pay out of pocket, Darbandi mentioned.

“Maybe hyaluronic acid injections have to be studied for ache administration extra completely,” he mentioned.

Corticosteroids are a quick approach to get ache aid and management irritation however won’t be choice for long-term remedy, Kim mentioned. Repeated injections can put sufferers in danger for different issues, akin to infections as a result of corticosteroids suppress your immune system, he mentioned.

Advertisement

And a few individuals could not see vital profit from both steroid or hyaluronic acid injections, Kim added.

For a long-term technique, Kim really helpful constructing a trusted workforce of well being care suppliers, together with your main care physician, orthopedic specialist, bodily therapist, nutritionist and rheumatologist.

It might be useful to handle weight and physique mass index, or BMI, to enhance metabolic results and scale back total irritation, Kim mentioned. It’s additionally essential to attempt to train and be bodily energetic, he mentioned, including that strolling has been confirmed to enhance arthritis.

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

News

Kamala Harris plans tax breaks for families in ‘laser-focused’ bid to ease cost of living crisis

Published

on

Kamala Harris plans tax breaks for families in ‘laser-focused’ bid to ease cost of living crisis

Unlock the US Election Countdown newsletter for free

Kamala Harris on Friday unveiled parts of her economic programme, including new tax relief for families and homebuyers and a crackdown on price gouging, as she tries to persuade voters she can tackle a cost of living crisis that has dogged the Biden administration.

The Democratic presidential candidate laid out the plans in a speech in North Carolina, a battleground state where her Republican rival Donald Trump delivered his own speech on economic policy earlier this week.

Trump and Harris are battling for votes with just over 80 days to go before November’s US presidential election. The Republican candidate has railed against inflation while vowing to drive down fuel and housing costs and setting out his own protectionist economic agenda.

Advertisement

Harris said that if elected president, she would be “laser-focused on creating opportunities for the middle class that advance their economic security, stability and dignity”. The vice-president said she would lay out more economic plans in the weeks to come, but on Friday focused on her proposals to reduce the cost of living.

“Look, the bills add up. Food, rent, gas, back to school, clothes, prescription medication, after all that, for many families, there’s not much left at the end of the month,” she said. “I will take on the high costs that matter most to most Americans.”

The most significant of Harris’s proposals include a $6,000 tax credit for families with newborn children, an expansion of an existing credit for families with older children to $3,600 per year, and up to $25,000 in downpayment support for first-time homebuyers.

Harris, who replaced President Joe Biden as the Democratic candidate last month, has pulled ahead of Trump in some polls but is under pressure to come up with her own detailed economic plan. Biden struggled to convince Americans that he had a plan to quell inflation, which jumped to a multi-decade high in 2022 but has drifted lower since then.

You are seeing a snapshot of an interactive graphic. This is most likely due to being offline or JavaScript being disabled in your browser.

Advertisement

Harris’s plan to make housing more affordable will also include a goal of building 3mn housing units in four years.

The vice-president will also try to ban so-called price gouging on food and groceries, designed to stop corporations from “unfairly” running up profits, and will propose giving the Federal Trade Commission and state attorneys-general the power to penalise companies that do not comply.

Harris and Trump have traded barbs in recent days over who would be better positioned to shepherd the US economy. Trump, a former real estate executive, on Thursday held a press conference at his New Jersey country club, flanked by groceries as he accused Harris of being a “radical California liberal who broke the economy, broke the border and broke the world, frankly”. On Friday, the Trump campaign said “comrade Kamala” had gone “full communist” by proposing to fix prices for consumer goods.

Harris on Friday sought to draw a contrast between Trump’s proposals, including a vow to extend his 2017 tax cuts for corporations and wealthy individuals, and her own.

“Donald Trump fights for billionaires and large corporations,” she said. “I will fight to give money back to working and middle-class Americans.”

Advertisement

You are seeing a snapshot of an interactive graphic. This is most likely due to being offline or JavaScript being disabled in your browser.

Trump has long enjoyed an advantage in the eyes of voters when it comes to economic issues. But the most recent FT-Michigan Ross poll found voters were slightly more likely to say they trusted Harris over Trump to handle the economy, with 42 per cent trusting Harris and 41 per cent backing Trump.

The University of Michigan’s index of consumer sentiment, which came out on Friday, showed sentiment among Democrats had improved by 6 per cent after Harris replaced Biden at the top of the presidential ticket, and rose 3 per cent among independents. Sentiment fell among Republicans by 5 per cent over the same period.

Additional reporting by Peter Wells and Eva Xiao in New York

Continue Reading

News

Over 100 of Donald Trump’s companies make no money: Financial disclosures

Published

on

Over 100 of Donald Trump’s companies make no money: Financial disclosures

Nearly half of former President Donald Trump’s financial assets returned no income—or income measured at less than $201—new financial filings show.

The documents were released by the Federal Election Commission and are the first public insight into the Republican presidential nominee’s earnings in the lead-up to the presidential election. The disclosure is more than 250 pages and lists all of Trump’s incomes, investments, debts and business interests. There is also a section dedicated to “Spouse’s Employment Assets & Income and Retirement Accounts” regarding Melania Trump’s income.

Under the section titled “Filer’s Employment Assets & Income and Retirement Accounts,” there are 452 listings, with income types including rent, royalties, interest, sales proceeds, management fees, license fees, business income and more. Of these listings, 205 returned no income or less than $201.

Former President Donald Trump speaks at the Conservative Political Action Conference on August 6, 2022, in Dallas, Texas. Trump’s financial filings were released this week and show that many of his businesses don’t return income….


Getty

Inactive assets accounted for 67 of Trump’s listings that returned no income or less than $201. Thirty-three of the listings returning no income were dissolved in 2023. Newsweek reached out to the Trump campaign by email for comment.

Despite the low income for so many of Trump’s assets, the Republican presidential nominee received a financial boost from many others, including $56.9 million in resort-related revenue at Mar-a-Lago. Other resorts in which Trump is involved also were lucrative, including TIGL Ireland Enterprises in Doonbeg, Ireland, which brought in more than $16 million in resort-related revenue.

Advertisement

Trump also raked in millions from several other holdings, including nearly $5 million from THC Miami Restaurant Hospitality LLC and more than $8 million from THC Sales & Marketing LLC based in New York. The Trump Corporation management company in New York and Florida brought in more than $24 million.

Trump’s various golf clubs across the nation proved especially lucrative, with Trump National Charlotte in North Carolina bringing in more than $25 million. Trump National Jupiter in Florida, which DJT Holdings owns 99 percent of, brought in $33.5 million in “golf-related revenue.” Trump National Washington, D.C., in Virginia earned more than $28 million, with Trump National Westchester in New York bringing in more than $12.7 million.

The filings also revealed some of Trump’s financial woes, such as owing more than $100 million in liabilities regarding his legal troubles in New York. Judgments against Trump in the two civil lawsuits brought against him by E. Jean Carroll are listed in the disclosure. The document also listed more than $50 million in liabilities stemming from the New York civil fraud case brought against Trump by New York Attorney General Letitia James.

Advertisement
Continue Reading

News

Bayer shares jump after key US court win in Roundup litigation saga

Published

on

Bayer shares jump after key US court win in Roundup litigation saga

Unlock the Editor’s Digest for free

Shares in German pills-to-weedkiller conglomerate Bayer jumped 11 per cent on Friday after the group scored a key win in a US appeals court over the labelling of its allegedly carcinogenic herbicide Roundup.

An appeals court in Philadelphia on Thursday ruled that Bayer did not violate US state law when it failed to add a cancer warning to its Roundup products, which uses glyphosate as its active ingredient.

Bayer has been ensnared in complex and costly legal battles over the weedkiller since 2018, fighting cases in multiple US states.

Advertisement

The Leverkusen-based firm, which became embroiled in the glyphosate litigation through its ill-fated $63bn takeover of US rival Monsanto in 2016, is facing damages claims from thousands of US citizens who blame Roundup for giving them cancer and accuse Bayer of failing to warn about the risk. The German conglomerate maintains that the product is safe and says scientific research supports that view.

The Third Circuit Court of Appeals in Philadelphia ruled unanimously on Thursday that federal regulations superseded a Pennsylvania state law, meaning Bayer did not need to place a warning on the pesticide.

The verdict opens the door for Bayer to have the legal issue reviewed by the US Supreme Court, as it is at odds with previous ones by other federal appellate courts.

The court said federal law required health warnings on pesticides to confirm to those required by the Federal Insecticide, Fungicide, and Rodenticide Act rather than state law.

The legal saga was caused by conflicting views of from different authorities on the potential carcinogenic effects of glyphosate. The US Environmental Protection Agency maintains its assessment that the chemical created “no risks of concern to human health when glyphosate is used in accordance with its current label.” But in 2015, the International Agency for Research on Cancer had labelled glyphosate as “probably carcinogenic to humans.”

Advertisement

In 2020, Bayer struck a $10.9bn settlement over a wave of Roundup lawsuits, and set aside another $4.5bn a year later. After losing several court cases, which dragged down the share price heavily, it embarked on a lobbying effort to persuade US states to pass legislation that would cut billions of dollars in liabilities and reduce the legal threat from the litigation saga.

Shares in Bayer were trading at €29.20 on Friday, having risen by 11 per cent in morning trading. The company’s stock is still down more than 40 per cent over the past 12 months, giving it a market valuation of €29bn.

Bayer said in a statement that it was “pleased” with the latest court ruling, adding that the decision created a “circuit split among the federal appellate courts and necessitates a review by the US Supreme Court to settle this important issue of law.”

If the Supreme Court were to share the view of the Philadelphia appeals court, Bayer would be off the hook over bulk of the glyphosate damage claims, according to a person familiar with the matter.

However, it may still decide not to review the case. Previous attempts by the company to get a supreme court ruling on the matter were unsuccessful.

Advertisement

Bayer on Friday said that it stands “fully behind its Roundup products”, arguing that “the weight of scientific evidence and the conclusions of expert regulators worldwide continue to support the safety of glyphosate-based herbicides and that they are not carcinogenic”.

Continue Reading
Advertisement

Trending